Error title
Some error text about your books and stuff.
Close

Helicobacter Pylori Basic Mechanisms to Clinical Cure 2000

by G.N.J. Tytgat

  • ISBN: 9780792387640
  • ISBN10: 0792387643

Helicobacter Pylori Basic Mechanisms to Clinical Cure 2000

by G.N.J. Tytgat

  • List Price: $279.99
  • Binding: Hardcover
  • Publisher: Kluwer Academic Pub
  • Publish date: 10/01/2000
  • ISBN: 9780792387640
  • ISBN10: 0792387643
used Add to Cart $18.64
You save: 93%
Marketplace Item
new Add to Cart $247.93
You save: 11%
FREE economy shipping!
Description: Section I: Helicobacter pylori -- The Organism.- 1 What are the biochemical and physiological implications of the new genetic information'.- 2 The urease system of Helicobacter pylori.- 3 The amphibiotic relationship of Helicobacter pylori and humans.- 4 Helicobacter pylori is pathogenic flora.- 5 Disease-specific Helicobacter pylori virulence factors: the role of cagA, vacA, iceA, babA2 alone or in combination.- Section II: Helicobacter pylori -- Epidemiology.- 6 Factors associated with disappearance of Helicobacter pylori in the West.- 7 Factors associated with disappearance of Helicobacter pylori in the Far East.- 8 Differences in prevalence of Helicobacter pylori and disease outcomes according to race/environmental factors in Southeast Asia.- Section III: Novel Helicobacters.- 9 Infection with Helicobacter heilmannii (formerly Gastrospirillum hominis): characterization, epidemiology and therapy.- 10 Hepatobiliary Helicobacters: recognized animal pathogens with suspected pathogenic potential in humans.- 11 Novel Helicobacter species in the intestine.- Section IV: Diagnosis of Helicobacter pylori Infection.- 12 Diagnosis of Helicobacter pylori infection: faecal antigen determination.- 13 Pitfalls in Helicobacter pylori diagnosis.- Section V: Inflammation and the Immune Response to Helicobacter pylori Infection.- 14 Overview of immune and inflammatory changes due to Helicobacter infection.- 15 Interaction of Helicobacter pylori with gastric epithelium.- 16 Helicobacter pylori and the epithelial barrier: role of oxidative injury.- 17 Immuno-inflammatory response to Helicobacter pylori in children.- 18 Severity and reversibility of mucosal inflammation in children and adolescents infected with Helicobacter pylori.- 19 Elimination of Helicobacter pylori is dependent on a Th2 response.- 20 Elimination of Helicobacter pylori is not dependent on a Th2 cytokine response.- 21 The inflammatory activity in Helicobacter pylori infection is predominantly organism related.- 22 The inflammatory activity in Helicobacter pylori infection is predominantly host-related.- Section VI: Helicobacter pylori and Gastritis.- 23 Helicobacter pylori gastritis -- a global view.- 24 Unusual forms of gastric inflammation and their relationship to Helicobacter pylori infection.- 25 Can atrophic gastritis be diagnosed in the presence of Helicobacter pylori infection'.- 26 Mechanisms involved in gastric atrophy.- 27 Intestinal metaplasia: types, mechanisms of origin, and role in gastric cancer histogenesis.- 28 Long-term proton pump inhibitor therapy accelerates the onset of atrophic gastritis in Helicobacter pylori-positive patients.- 29 Proton pump inhibitors do not accelerate the development of gastric atrophy in Helicobacter pylori gastritis.- 30 Autoimmune gastritis via mimicking does occur.- 31 Autoimmune gastritis and antigenic mimicking.- 32 Carditis and intestinal metaplasia of the cardia is reflux related.- 33 Carditis and cardia intestinal metaplasia are Helicobacter pylori-related.- 34 Is gastric metaplasia in Helicobacter pylori really gastric'.- Section VII: Helicobacter pylori and Clinical Consequences.- 35 Extragastric manifestations of Helicobacter pylori -- are they relevant'.- 36 Peptic ulcer disease -- the transitional zones are important.- 37 What causes Helicobacter pylori-negative non-NSAID-related ulcers'.- 38 From the pump to the helix.- 39 Mechanisms involved in the development of hypochlorhydria and pangastritis in Helicobacter pylori infection.- 40 Effect of Helicobacter pylori infection on gastric acid control using proton pump inhibitors.- 41 Rebound acid hypersecretion after acid-suppressive therapy.- 42 Gastric consequences of proton pump therapy and Helicobacter pylori eradication.- Section VIII: Helicobacter pylori, Dyspepsia and NSAIDs.- 43 Current concepts of dyspepsia: the role of the nervous system.- 44 How to explain outcome differences in dyspepsia studies.- 45 Helicobacter pylori eradication for dyspepsia is clinically useful.- 46 Dyspepsia is no indication for Helicobacter pylori eradication.- 47 Role of Helicobacter pylori infection in NSAID-associated gastropathy.- 48 Role of Helicobacter pylori in NSAID gastropathy: can Helicobacter pylori infection be beneficial'.- 49 Helicobacter pylori and non-steroidal anti-inflammatory drugs.- Section IX: Helicobacter pylori and ''Test-and-Treat'' Strategies.- 50 The impact of a ''test-and-treat'' strategy for Helicobacter pylori: the United States perspective.- 51 Test-and-treat strategy in dyspepsia -- the European perspective.- 52 The impact of the ''test-and-treat'' strategies for Helicobacter pylori infection -- an Asian perspective'.- Section X: Helicobacter pylori and Gastric Malignancy.- 53 Rodent models for Helicobacter-induced gastric cancer.- 54 Helicobacter pylori and gastric cancer: the risk is real.- 55 Helicobacter pylori in gastric malignancy: role of oxidants, antioxidants and other co-factors.- 56 Gastric markers of pre-malignancy are not reversible.- 57 The case for the reversibility of gastric dysplasia/neoplasia.- 58 Evaluation of the long-term outcome of Helicobacter pylori-related gastric mucosa-associated lymphoid tissue (MALT) lymphoma.- Section XI: Treatment of Helicobacter pylori Infection.- 59 Current state-of-the-art management for Helicobacter pylori infection: global perspective.- 60 Guidelines for therapy of Helicobacter pylori infection -- a world perspective.- 61 Bismuth triple and quadruple studies for Helicobacter pylori eradication in Canada.- 62 Approach to Helicobacter pylori infection in children.- 63 What role for clarithromycin in the treatment of Helicobacter pylori infection'.- 64 What is the role of bismuth in Helicobacter pylori antimicrobial resistance'.- 65 Risk factors for failure of Helicobacter pylori eradication therapy.- 66 Strategies for therapy failures: choice of ''back-up'' regimen determined by primary treatment for Helicobacter pylori infection.- 67 Quadruple should be first-line therapy for Helicobacter pylori infection.- 68 Quadruple therapy should be secondline treatment for Helicobacter pylori infection.- 69 Helicobacter pylori infection: expectations for future therapy.- 70 A Helicobacter pylori vaccine is essential.- Section XII: Helicobacter Infections and the Future.- 71 The agenda for the microbiologist.- 72 The agenda for the immunologist.- 73 The agenda for the histopathologist.- 74 Helicobacter infections in the new millennium: the challenge for the clinician.
Expand description
Seller Condition Comments Price  
Seller: Ergodebooks
Location: Richmond, TX Ask seller a question
Condition: Good
Buy with confidence. Excellent Customer Service & Return policy.Ships Fast. 24*7 Customer Service.
Price:
$18.64
Comments:
Buy with confidence. Excellent Customer Service & Return policy.Ships Fast. 24*7 Customer Service.
please wait
Please Wait

Notify Me When Available

Enter your email address below,
and we'll contact you when your school adds course materials for
.
Enter your email address below, and we'll contact you when is back in stock (ISBN: ).